Zimmer Biomet (ZBH) Under Investigation for Misleading Revenue Guidance Amid Order Cancellations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Globenewswire
- Revenue Target Scrutiny: Zimmer Biomet expressed “very high” confidence in its 2025 revenue growth during the August earnings call, projecting organic growth of 3.5% to 4.5%, but subsequent order cancellations in emerging markets led to a significant revenue miss in Latin America, causing a 15% stock drop on November 5.
- Severe Market Reaction: The company reported only 5% organic revenue growth in its November earnings, lowering its growth forecast to 4%, indicating that cancellations in emerging markets significantly pressured performance, which severely undermined market confidence in management.
- Management Confidence Eroded: CEO Ivan Tornos acknowledged the need for “more measured” external commentary in response to analyst scrutiny, highlighting the company's vulnerability in facing market challenges and potentially diminishing investor trust moving forward.
- Legal Investigation Initiated: Hagens Berman is investigating whether Zimmer Biomet violated federal securities laws by issuing overly optimistic guidance while concealing operational disruptions, which may have resulted in substantial investor losses.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ZBH
Wall Street analysts forecast ZBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZBH is 100.47 USD with a low forecast of 88.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
4 Buy
11 Hold
3 Sell
Hold
Current: 85.710
Low
88.00
Averages
100.47
High
120.00
Current: 85.710
Low
88.00
Averages
100.47
High
120.00
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ZBH's 15% Stock Drop Triggers Investigation into Revenue Guidance
- Stock Price Plunge: Zimmer Biomet's stock dropped 15% due to reduced revenue guidance for 2025, significantly erasing market value and raising investor concerns about management's credibility.
- Crisis of Confidence: Despite management's claims of “very high” confidence in August 2025 regarding second-half growth, subsequent cancellations and revenue misses revealed potential misleading optimism about its international business stability.
- Legal Investigation Launched: Hagens Berman is investigating whether Zimmer Biomet violated federal securities laws by issuing overly optimistic guidance while concealing operational disruptions, which may have led to substantial investor losses.
- Investor Action Call: The firm urges affected investors to submit claims and provided contact information for participation in the investigation, highlighting a strong focus on corporate governance and transparency.
Continue Reading
Latest Ratings and Outlook from Wall Street
- Cantor's Positive Outlook on Strategy: Cantor Fitzgerald initiates Strategy with an overweight rating, suggesting that the crypto company is well-positioned for the bitcoin cycle, indicating now is a compelling time to invest in this financial engineering innovator.
- Citi's Bullish Stance on Novartis: Citi initiates Novartis as a buy, forecasting 4-5% sales growth for 2025-2030, which exceeds the consensus estimate of 3.5-4.0%, highlighting the company's consistent earnings performance.
- TD Cowen Upgrades Zimmer Biomet: TD Cowen upgrades Zimmer Biomet from hold to buy, citing the company's commitment to innovation and management strategies that are expected to drive stock price appreciation.
- Morgan Stanley Downgrades Alcoa: Morgan Stanley downgrades Alcoa from overweight to equal weight, noting that the stock has significantly outperformed peers recently, leading to a more balanced risk-reward scenario.
Continue Reading